Fortress Biotech (NASDAQ: FBIOP) issues June 30 2025 results release

(Moderate)

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Fortress Biotech, Inc. furnished a press release that provides a corporate update and announces its financial results for the quarter ended June 30, 2025.

The press release is included as Exhibit 99.1 and is furnished, not filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Accepted by SEC EDGAR 08/14/2025 - 04:10 PM

FAQ

What did Fortress Biotech (FBIOP) disclose in this 8-K?

Fortress Biotech furnished a press release providing a corporate update and announcing financial results for the quarter ended June 30, 2025. The release is attached as Exhibit 99.1 to the report.

Which period do Fortress Biotech (FBIOP)’s results in this filing cover?

The financial results discussed relate to Fortress Biotech’s quarter ended June 30, 2025. Details of the company’s performance for this period are contained in the press release furnished as Exhibit 99.1.

How is the Fortress Biotech (FBIOP) press release treated legally in this 8-K?

The press release is being furnished, not filed, under the Exchange Act. This means it is not subject to Section 18 liabilities and is not automatically incorporated into Securities Act filings without specific reference.

Where can investors find the Fortress Biotech (FBIOP) corporate update details?

Investors can find the full corporate update and quarterly financial information in the press release attached as Exhibit 99.1 to the report. The 8-K itself mainly identifies and furnishes this exhibit.

What exhibits did Fortress Biotech (FBIOP) include with this 8-K?

Fortress Biotech included Exhibit 99.1, a press release dated August 14, 2025, and Exhibit 104, the cover page interactive data file with embedded Inline XBRL tags, as part of the submission.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 14, 2025

Fortress Biotech, Inc.

(Exact Name of Registrant as Specified in Charter)


Delaware (State or Other Jurisdiction of Incorporation)		001-35366 (Commission File Number)		20-5157386 (IRS Employer Identification No.)

1111 Kane Concourse, Suite 301

Bay Harbor Islands, FL 33154

(Address of Principal Executive Offices)

(781) 652-4500

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act.

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

☐Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	FBIO	Nasdaq Capital Market
9.375% Series A Cumulative Redeemable Perpetual Preferred Stock	FBIOP	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 14, 2025, Fortress Biotech, Inc. issued a press release to provide a corporate update and to announce its financial results for the quarter ended June 30, 2025. A copy of such press release is being furnished as Exhibit 99.1 to this report.

The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished herewith:

99
Exhibit Number		Description
99.1		Press Release, dated August 14, 2025
104		Cover Page Interactive Data File (the cover page XBRL tags are imbedded in the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Fortress Biotech, Inc.
	(Registrant)

Date: August 14, 2025

	By:	/s/ Lindsay A. Rosenwald, M.D.
		Lindsay A. Rosenwald, M.D.
		Chairman, President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR